Menu Search

Company Announcements

Gossamer Bio Inc

Gossamer Bio to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Aug. 29, 2025-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September.

Cantor Global Healthcare Conference

 

Date / Time:

September 3rd, at 9:10 AM ET

Format:

Fireside Chat & 1x1’s

Location:

New York, NY

Webcast Link:

https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=93028624&checkCompany=1&checkEmail=1&checkName=1

Wells Fargo Healthcare Conference

 

Date / Time:

September 4th

Format:

1x1’s

Location:

Boston, MA

H.C. Wainwright 27th Annual Global Healthcare

 

Date / Time:

September 9th, at 8:00 AM ET

Format:

Fireside Chat & 1x1’s

Location:

New York, NY

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

For Investors and Media
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com

Source: Gossamer Bio, Inc.